People · Operator
Named in public records as an officer, director or promoter · active 2011–2023 · Biotech / Pharma, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Vedanta Biosciences, Inc. | — | Biotech / Pharma | Series D+ | $240.3M | $2.0B | 2023 |
| Gelesis Inc | — | Biotechnology | Series B | $37.7M | $1.3B | 2011 |
John LaMattina at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside John LaMattina on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Rishi Gupta | 1 | 12 |
| Elon Boms | 1 | 10 |
| Curt LaBelle | 1 | 7 |
| Martin Heidecker | 1 | 6 |
| Eric Elenko | 1 | 4 |
| NEIL TIWARI | 1 | 4 |
| Robert Forrester | 1 | 4 |
| Bharatt Chowrira | 1 | 3 |
| Troy Ignelzi | 1 | 3 |
| Christopher Viehbacher | 1 | 2 |
| Bennett Shapiro | 1 | 2 |
| Meghan Fitzgerald | 1 | 2 |
| Elliot Maltz | 1 | 2 |
| Yishai Zohar | 1 | 2 |
| Bharatt M. Chowrira | 1 | 1 |
| Mendy Axelrad | 1 | 1 |
| Charles Sherwood | 1 | 1 |
| Susan Dillon | 1 | 1 |
| Daniel Couto | 1 | 1 |
| Bernat Olle | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.